Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03897439 · ClinicalTrials.gov registry record · Phase 3
Individualizing Pharmacotherapy for African American Smokers
A Phase 3 study of Smoking Cessation, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 392
- Enrollment target
- 1
- Study location
NCT03897439 is a Phase 3 study of Smoking Cessation that has completed, run by University of Kansas Medical Center. The registered enrollment target is 392 participants, below the 473-participant average among 188 other Smoking Cessation trials with a reported enrollment target (17% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03897439, a Phase 3 study of Smoking Cessation, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 392 participants
- Enrollment target
- 1
- Study location
Study Summary
Improving cessation outcomes for African American smokers through the use of novel, empirically-based strategies is a national health priority. In the vast majority of smoking cessation studies and in clinical practice, when smokers are provided a medication to help them quit, they are expected to continue that medication regardless of how well it is working. This study will assess whether African Americans smokers respond better if they continue with a single treatment or if their treatment is changed when that treatment is not working.
Conditions Studied
Interventions
- DRUG Varenicline Tartrate
- DRUG Bupropion
- DRUG Nicotine patch
Study Locations (1)
Missouri
- Swope Health Central - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 392 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2022-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03897439
The ClinicalTrials.gov registry entry for NCT03897439 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 392 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 473-participant average among 188 other Smoking Cessation trials with a reported enrollment target (17% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 3 interventions - of which Varenicline Tartrate is the first listed.
NCT03897439 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT03897439 about?
NCT03897439 is a clinical study titled "Individualizing Pharmacotherapy for African American Smokers". Improving cessation outcomes for African American smokers through the use of novel, empirically-based strategies is a national health priority. In the vast majority of smoking cessation studies and in clinical practice, when smokers are provided a medication to help them quit, they are expected to c...
What is the current status of trial NCT03897439?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 392 participants. The study started on 2019-05-01. Estimated completion is 2022-01-30.
What conditions does trial NCT03897439 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT03897439?
The interventions under investigation include: Varenicline Tartrate (DRUG), Bupropion (DRUG), Nicotine patch (DRUG).
Who is sponsoring clinical trial NCT03897439?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03897439 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tobacco Education and Lung Health Study (TEAL)
RECRUITING · Phase 3
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
-
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
RECRUITING · Phase 3
-
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
COMPLETED · Phase 3
-
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
COMPLETED · Phase 3
-
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.